리메드

302550KOSDAQ

42.0 / 100

Reference Date: 2026-09-08

Financial Score16.5 / 40

News Sentiment12.5 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 9.0% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Remed is a company specializing in developing and manufacturing medical devices that utilize non-invasive magnetic stimulation technology to treat various conditions such as depression, stroke, and chronic pain. Its key products, BrainStim and ALTMS, have received FDA and KFDA certifications for depression treatment and are expanding globally. The company also offers chronic pain management through NMS and aesthetic services via CSMS.

Number of Employees

114people

Average Salary

46.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

157.94Industry Average 15.000.0Point

10.5x industry avg (risky)

PBR

2.06Industry Average 1.201.0Point

1.7x industry avg (risky)

ROE

-0.09Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

12.60Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20257.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲16.9% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲52.0% (2-year basis)

ROE Trend

2.0 / 4

Avg ROE 7.2% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (13%, downtrend)

Current 2,685Won52-week high 3,98552-week low 2,485

1-month return1.0Point

1m -8.98% (falling)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-08-26
Neutral주식등의대량보유상황보고서(일반)2026-08-20
Neutral반기보고서 (2026.06)2026-08-12